Please assess the completion status of the following clinical trial:

Trial Title: Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of moderate stable Chronic Obstructive Pulmonary.~* Disease with FEV1/FVC \<0.7 at screening.~* Woman of non-childbearing potential.~* Female participants of childbearing potential must test negative for pregnancy and must be using a highly effective method of birth control during the study and for at least 1 month after completion of study dosing.~* Female participants must not be breastfeeding.~* Men must agree to use a highly effective method of birth control with partners of childbearing potential during the study and for 1 month after completion of study dosing.~* Current or past smoking history \>10 pack-years.~* Must be capable of performing reproducible spirometry maneuvers.~Exclusion Criteria:~* History of significant respiratory disease other than COPD, and/ or requires daily long-term oxygen therapy.~* Exacerbation of COPD, lung infection within 6 weeks prior to study.~* Start of or change in dose of COPD treatment 4 weeks before study.~* Daily using of maintenance systemic/inhaled corticosteroids (\>1000 microgram of fluticasone propionate equivalent or \>5 mg prednisone).~* Use of bronchodilators or medication for the treatment of COPD, aspirin, anti-inflammatories for a specific time, prior to the first dose or is not willing to abstain from their use for the specified time periods prior to study dose administration.~* Symptomatic prostrate hypertrophy, bladder neck obstruction, active cancer, narrow angle glaucoma.~* Clinical significant hypersensitivity to medications.~* Participants have an uncontrolled hematologic, immunologic, renal, neurologic, hepatic, endocrine or other disease that may place participant at risk.~* Cerebrovascular, cardiovascular disease or abnormal ECG.~* History of drug or alcohol abuse.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sequence 1 (Type: EXPERIMENTAL): Period 1 = Placebo; Period 2 = TD-4208 700 μg; Period 3 = TD-4208 350 μg; Period 4 = Ipratropium 500 μg
- Sequence 2 (Type: EXPERIMENTAL): Period 1 = TD-4208 700 μg; Period 2 = Ipratropium 500 μg; Period 3 = Placebo; Period 4 = TD-4208 350 μg
- Sequence 3 (Type: EXPERIMENTAL): Period 1 = TD-4208 350 μg; Period 2 = Placebo; Period 3 = Ipratropium 500 μg; Period 4 = TD-4208 700 μg
- Sequence 4 (Type: EXPERIMENTAL): Period 1 = Ipratropium 500 μg; Period 2 = TD-4208 350 μg; Period 3 = TD-4208 700 μg; Period 4 = Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).